Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
3.020
+0.095 (3.25%)
At close: May 12, 2025, 4:00 PM
3.000
-0.020 (-0.66%)
After-hours: May 12, 2025, 7:48 PM EDT
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 5.67, with a low estimate of 3.00 and a high estimate of 8.00. The average target predicts an increase of 87.75% from the current stock price of 3.02.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Cytek Biosciences stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Total | 3 | 3 | 3 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $3.5 → $3 | Strong Sell | Maintains | $3.5 → $3 | -0.66% | May 12, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +98.68% | Mar 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +164.90% | Mar 4, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $8.5 | Buy | Maintains | $8 → $8.5 | +181.46% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +164.90% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
208.52M
from 200.45M
Increased by 4.02%
Revenue Next Year
226.19M
from 208.52M
Increased by 8.47%
EPS This Year
-0.05
from -0.05
EPS Next Year
-0.00
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 218.4M | 244.6M | 279.6M |
| Avg | 208.5M | 226.2M | 258.6M |
| Low | 194.0M | 199.6M | 227.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 8.9% | 17.3% | 23.6% |
| Avg | 4.0% | 8.5% | 14.3% |
| Low | -3.2% | -4.3% | 0.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.02 | 0.13 | 0.19 |
| Avg | -0.05 | -0.00 | 0.08 |
| Low | -0.07 | -0.07 | 0.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.